Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bedside CD19 CAR T-cell Therapy for B-ALL
NCT07277504Phase 1Not yet recruiting
- Sponsor
- General Hospital of Western Theater Command of PLA
- Start
- Dec 2025
- Primary completion
- Dec 2030
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of UCD19 CAR-T in B cell acute lymphoblastic leukemia (B-ALL), sponsored by General Hospital of Western Theater Command of PLA. Primary endpoints: Incidence rate of CAR-T-related adverse events at 28 days and Incidence rate of Dose-Limiting Toxicities at 28 days. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
UCD19 CAR-T
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT07277504.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07277504.